The Michael J. Fox Foundation for Parkinson’s Research has awarded Aliso Viejo-based Avanir Pharmaceuticals Inc. a grant to test AVP-923, a new drug that aims to treat levodopa-induced-dyskinesia (LID) in Parkinson’s disease, an affliction that impairs one’s ability to control his muscles and movements.
LID occurs in most patients with Parkinson’s disease and leads to other motor complications.
"The development of effective drugs that can reliably suppress L-dopa-induced dyskinesia is a very high priority in Parkinson's research," said Anthony E. Lang, professor and director of the Division of Neurology, and the chair for Parkinson's disease research at the University of Toronto.
Avanir will conduct an experiment using study participants that will compare AVP-923 with a placebo for treatment of LID, the results of which will determine the future development of the drug.
"We are proud to be recognized by the Michael J. Fox Foundation with this award," said Joao Siffert, senior vice president of research and development at Avanir, and the main investigator of the study. "Their support will enable this important study in LID and further validates the rationale for testing AVP-923 for diverse central nervous system disorders of high unmet medical need."
Aliso Viejo’s AVANIR announces positive study results
Aliso Viejo’s AVANIR raises $10.6 million in stock sale
AVANIR launches campaign promoting new PBA drug